Natural Selection Cuts Broad Swath Through Fruit Fly Genome
By Nicholas Wade,
New York Times
| 09. 20. 2010
A new exploration of how evolution works at the genomic level may have a significant impact on drug development and other areas of medicine.
The report, published in Nature last week, offers new evidence in a longstanding debate about how organisms evolve. One well-known path to change is a heavily favorable mutation in a single gene. But it may be well known only because it is easy to study. Another path is exploitation of mildly favorable differences that already exist in many genes.
The question has considerable practical importance because if complex traits, including susceptibility to disease, are influenced by just a few genes, then it should be easy to develop treatments that target the few genes’ products. But if tens or hundreds of genes are involved in each trait, the task may be close to impossible.
Theorists have argued over this point for years, but researchers have been able to address it only recently. With advanced DNA decoding machines they can now afford to decode every DNA unit in sample genomes of a population undergoing an evolutionary change.
Three...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...